Patients with B-ALL who are resistant to or relapse after CD19-targeted immunotherapies have few treatment options, however CARs targeting CD22 have shown promising efficacy and safety in early phase trials for several B cell cancers [71]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.